Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
NCT06532656Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2024
- Primary completion
- Jul 2030
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label trial of bictegravir and lenacapavir in human immunodeficiency virus infection (HIV) (3 cohorts), sponsored by Gilead Sciences. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve Over the Dosing Interval and 3 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
bictegravirlenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06532656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532656.